Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Gun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of Interest'Science Spin' Found Prevalent in Biomedical LiteratureHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening CompletionMany Americans Getting Medical Care They Don't NeedInsurer Aetna's Envelopes Revealed Customers' HIV StatusHealth Groups Demand 'R' Rating for Movies That Show SmokingGoogle Search for 'Depression' Now to Provide Screening TestPatients' Hearing Loss May Mean Poorer Medical CareFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?Steep Price Hikes Led to Drop in Use of 2 Heart Drugs at U.S. HospitalsAPA: Medical Discrimination Based on Size Stresses Patients2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryMedical Reality Catches Up to Science FictionFDA Looks to Reduce Nicotine in CigarettesAHA Hands-Only CPR Training Kiosks Available at More Airports$100 Sweetens the Pot for a ColonoscopyJust a Few Vaccine Refusers Could Endanger ManyASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: StudyPatient Involvement Can Cut Errors in X-Ray ImagingMarket Competition Linked to Change in Generic Drug Prices
Questions and AnswersLinksBook Reviews
Related Topics

Median Cost of Cancer Drug Development $648.0 Million


HealthDay News
Updated: Sep 11th 2017

new article illustration

MONDAY, Sept. 11, 2017 (HealthDay News) -- The median cost of cancer drug development is $648.0 million, and revenue after approval is substantial, according to a study published online Sept. 11 in JAMA Internal Medicine.

Vinay Prasad, M.D., M.P.H., from the Oregon Health and Science University in Portland, and Sham Mailankody, M.B.B.S., from the Memorial Sloan Kettering Cancer Center in New York City, estimated cumulative research and development (R&D) spending from initiation of drug development activity to date of approval for cancer drugs. The analysis included 10 companies and drugs.

The researchers found that the median time to develop a drug was 7.3 years for the 10 companies. Five of the drugs received accelerated approval from the U.S. Food and Drug Administration, and five received regular approval. Drug development cost a median of $648.0 million. The median cost was $757.4 million and $793.6 million for a 7 percent per annum cost of capital and for a 9 percent opportunity costs, respectively. The total revenue from sales of these 10 drugs was $67.0 billion with a median of 4.0 years since approval, compared with $7.2 billion in total R&D spending.

"The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates," the authors write. "This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing."

One author disclosed financial ties to the biopharmaceutical industry; the second received fees for speaking at conferences in the health care industry.

Abstract/Full Text
Editorial